Skip to main content
. Author manuscript; available in PMC: 2019 Jul 6.
Published in final edited form as: Lancet Respir Med. 2016 Jun 10;4(8):617–626. doi: 10.1016/S2213-2600(16)30121-7

Figure 2:

Figure 2:

Percentage of patients with ≥5% and ≥10% average relative increases from baseline in ppFEV1 at weeks 16 and 24 in patients with ppFEV1 <40 or ≥40 at baseline (A) and ppFEV1 <70 or ≥70 at screening (B)

IVA=ivacaftor; LUM=lumacaftor; ppFEV1=percent predicted forced expiratory volume in 1 second; q12h=once every 12 hours; qd=once daily.